Niharika Samala, MD
Gastroenterology · Royal Oak, MINPI 1023266541
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $27,548 of the $31,217 with a category attached, or 88.2%. Novo Nordisk accounts for 99.2% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2024 at $28,243 and has fallen 89.9% since, to $2,847 in 2025. Among gastroenterology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 15 payments — averaging $2081.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$31K
- Madrigal Pharmaceuticals$234
Across 148 payments — averaging $4226.87 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$291K
- Eli Lilly$155K
- Regeneron$152K
- Astrazeneca UK Limited$28K
What the payments were for
- Consulting fees$27,54888%
- Travel & lodging$2,9209%
- Food & beverage$6852%
- Education$650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $30,983 |
| Madrigal Pharmaceuticals | 2 | $234 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZDIFFRA$135
How this compares
$31,217 in reported general payments places this provider in the 90th percentile of 497 gastroenterology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 43 | $137,077 |
| Ursodiol | 61 | $11,678 |
| Entecavir | 17 | $3,270 |
| CholestyramineCholestyramine (With Sugar) | 13 | $1,477 |
| Lactulose | 57 | $1,445 |
| Spironolactone | 91 | $1,417 |
| Sirolimus | 11 | $1,130 |
| Pantoprazole Sodium | 85 | $994 |
| Carvedilol | 69 | $444 |
| Azathioprine | 11 | $422 |
| Omeprazole | 25 | $388 |
| Furosemide | 82 | $292 |
| Hydroxyzine Hcl | 16 | $244 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 12 | $180 |
| Torsemide | 11 | $159 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Royal Oak
- Mohamad AlsibaeRoyal Oak$127K
- Mohamed AbdallahRoyal Oak$23K
- Kimberly BrownDetroit$733K
- Dilip MoonkaDetroit$611K
- Philip SchoenfeldAnn Arbor$539K
- Michelle Muza-MoonsAnn Arbor$481K
- Partha NandiTroy$377K
- Bradford WhitmerSaint Clair Shores$206K
- Mohammed BarawiSt Clair Shores$193K
- Stuart GordonDetroit$178K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.